Fostamatinib ITP denied as non-formulary by Aetna?

Aetna's specific coverage criteria for fostamatinib itp are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies Fostamatinib as Non-Formulary

Aetna's formulary (drug list) assigns every covered medication to a tier. Fostamatinib (Tavalisse) for ITP is a specialty medication that Aetna may place on a restricted or non-formulary tier, meaning it is not automatically covered under your benefit plan without additional authorization. A non-formulary denial is not a clinical judgment — it is an administrative classification — and it is one of the most commonly overturned denial types at appeal.

## Why This Denial Is Appealable

Formularies are not final. ACA §2719 and most state laws require insurers to have a formal exceptions process. A formulary exception (also called a medical-necessity exception or non-formulary exception) allows your prescriber to argue that no formulary alternative is clinically appropriate for your specific case. If fostamatinib has FDA approval for your condition and formulary alternatives have failed or are not suitable, a formulary exception appeal has strong legal and clinical footing.

## Federal Appeal Framework

• Formulary exception / internal appeal: File simultaneously or sequentially depending on your plan. The exception request triggers Aetna's internal review process under ERISA §503 full-and-fair review standards.
• External review: If the exception is denied and internal appeal exhausted, you have approximately four months to request binding external review by an independent organization.
• Expedited track: Available when your condition requires faster action; request this in writing and state the clinical urgency.

## Documentation to Gather

1. Formulary alternative history — records showing each formulary ITP drug that was tried, with dates, doses used (as documented in your chart), and documented reason for failure, intolerance, or contraindication. 2. Diagnosis and severity records — hematology notes, lab trends, and any hospitalization or bleeding history tied to inadequately controlled ITP. 3. Prescriber attestation — a letter from your hematologist stating why each formulary alternative is not clinically appropriate and why fostamatinib is medically necessary for your individual case. 4. FDA label and Aetna policy — attach the FDA-approved prescribing information confirming the indication, and request Aetna's current coverage/formulary policy in writing so you can respond to each stated criterion.

## Criteria-Mapping Structure

Obtain Aetna's formulary exception criteria and list each one. For every criterion, document the chart fact that satisfies it. Where a formulary alternative is listed as a required step, show it was completed with dates and outcomes. This structured response demonstrates clinical necessity and procedural compliance in a single document.